2005年1月,就有100多种新式减肥药居于研究制造阶段或者临床试验阶段,利莫那班(Acomplia)是此中最具远景的药物之一,它效用于脑细胞中一种叫做内川军素的卵白质。
基于430个网页-相关网页
Sanofi suspended sales of Acomplia last month, after the European version of the FDA said the drug's psychiatric side effects outweighed its benefits.
赛诺菲在欧洲的药品食品监督管理局宣布Acomplia的神经副作用超过其有效作用后,于上个月暂停其销售。
The FDA advisory panel that just dissed Acomplia, Sanofi-Aventis's weight-loss drug, dealt an indirect blow to a frequent and outspoken critic of the drug industry.
FDA顾问小组对赛诺菲一安万特公司的减肥药-利莫那班的否决,间接打击了医药工业中对此药频繁地公开评论。
Adverse effects include dizziness, nausea, anxiety, depressed mood and headaches and were found to be at 9.4 percent for those on Acomplia and 2.1 percent for those on placebo.
服用Acomplia的患者中9.4%的人出现包括头晕、恶心、焦虑、情绪失落及头痛的严重不良反应,而对照组出现这些不良反应的比例为2.1%。
应用推荐